Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients.

Frank M P van HarenLex M van LoonAnne SteinsThomas L SmootCaitlin SasSabrina StaasAlicia B VilasecaRuben A BarberaGustavo VidmarHugo BeccariFrida PopilevskyEleonora DaribayevaBhuvaneshwari VenkatesanSusan MozesRachel PostelNatalie PopilevskiAndrew James WebbQuentin NunesJohn Gerard LaffeyAntonio ArtigasRoger SmithBarry DixonAlice RichardsonHwan-Jin YoonClive Page

Published in: British journal of clinical pharmacology (2022)

Inhaled nebulised UFH in hospitalised patients with COVID-19 was safe. Although statistically significant, inhaled nebulised UFH did not produce a clinically relevant increase in APTT (peak values in the normal range). Urgent randomised evaluation of nebulised UFH in patients with COVID-19 is warranted and several studies are currently underway.

Keyphrases

cystic fibrosis
clinical trial
end stage renal disease
ejection fraction
study protocol
chronic kidney disease
newly diagnosed
open label
double blind
patient reported outcomes
patient reported